EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Royalty Pharma's enterprise value is $17,485 Mil.
Royalty Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,355 Mil. Therefore, Royalty Pharma's EV-to-Revenue for today is 7.43.
The historical rank and industry rank for Royalty Pharma's EV-to-Revenue or its related term are showing as below:
RPRX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 10.04 Med: 12.45 Max: 16.34
Current: 7.43
During the past 7 years, the highest EV-to-Revenue of Royalty Pharma was 16.34. The lowest was 10.04. And the median was 12.45.
RPRX's EV-to-Revenue is ranked better than 50.24% of 1031
companies
in the Biotechnology industry
Industry Median: 7.7
vs RPRX: 7.43
As of today (2024-04-23), Royalty Pharma's stock price is $27.83.
Royalty Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.90. Therefore, Royalty Pharma's PS Ratio for today is 7.13.
Royalty Pharma EV-to-Revenue Historical Data
The historical data trend for Royalty Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Royalty Pharma Annual Data
Trend
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
-
13.04
11.36
11.67
8.92
Royalty Pharma Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
11.67
10.41
9.14
8.60
8.92
Competitive Comparison
For the Biotechnology subindustry, Royalty Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Royalty Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's EV-to-Revenue falls into.
Royalty Pharma's current Enterprise Value is $17,485 Mil.
Royalty Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,355 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma's share price for today is $27.83.
Royalty Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Royalty Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Royalty Pharma (Royalty Pharma) Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RPRX has been successfully added to your 